European Medical Solutions's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 77.16.
European Medical Solutions's Days Inventory for the
six
months ended in Dec. 2025 was 143.81.
European Medical Solutions's Days Payable for the
six
months ended in Dec. 2025 was 135.13.
Therefore, European Medical Solutions's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 85.84.
European Medical Solutions (STU:AS00) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
European Medical Solutions Cash Conversion Cycle Related Terms
European Medical Solutions Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
European Medical Solutions Cash Conversion Cycle Chart
STU:AS00 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, European Medical Solutions's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
European Medical Solutions Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, European Medical Solutions's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where European Medical Solutions's Cash Conversion Cycle falls into.
European Medical Solutions Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
European Medical Solutions's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
European Medical Solutions (STU:AS00) has a Cash Conversion Cycle of 85.84 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on European Medical Solutions and its competitors.
Is European Medical Solutions' Cash Conversion Cycle too high?
European Medical Solutions' current Cash Conversion Cycle is 85.84. The Biotechnology industry median Cash Conversion Cycle is 103.08. European Medical Solutions' value of 85.84 is 16.7% below this industry median. Overall, European Medical Solutions has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' Cash Conversion Cycle compare to VRTX and REGN?
European Medical Solutions' Cash Conversion Cycle of 85.84 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.08. European Medical Solutions' value of 85.84 is 16.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.08, based on 871 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. European Medical Solutions's current Cash Conversion Cycle of 85.84 is 16.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on European Medical Solutions and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. European Medical Solutions's current Cash Conversion Cycle is 85.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
European Medical Solutions (STU:AS00) has a current Cash Conversion Cycle of 85.84. The stock's GF Value™ is €8.11, compared to a current price of €4.80 — trading 40.8% below its estimated fair value. The current Cash Conversion Cycle is 85.84 and 16.7% below the Biotechnology industry median of 103.08. European Medical Solutions' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current Cash Conversion Cycle is 85.84 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is European Medical Solutions (STU:AS00) Overvalued in 2026?
Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued.
The current stock price of €4.80 is trading 40.8% below its estimated GF Value™ of €8.11.
Key valuation signals for STU:AS00:
Cash Conversion Cycle: 85.84
GF Value™: €8.11 vs. price of €4.80 (40.8% below fair value)
Industry Position: 16.7% below the Biotechnology median
No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
50GF Score
Get the complete analysis for STU:AS00
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AS00 has been successfully added to your 
